￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Medical News

Efficacy and safety data of crizotinib (Xalkori) in non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Safety and tolerability of crizotinib in the treatment of positive non-small cell lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
Targeted drug for the treatment of ROS1 rearranged lung cancer: Crizotinib

2025-10-19 11:44:20

Check Details
Crizotinib is highly effective against ROS1 rearrangement in advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Crizotinib is a targeted drug for the treatment of patients with ROS1-positive advanced lung cancer

2025-10-19 11:44:20

Check Details
First-line treatment for ALK-positive lung cancer-crizotinib

2025-10-19 11:44:20

Check Details
Research progress of Lorlatinib in ALK-positive lung cancer

2025-10-19 11:44:20

Check Details
The third generation ALK/ROS1 mutated lung cancer targeting drug: lorlatinib

2025-10-19 11:44:20

Check Details
Analysis of efficacy and adverse reactions of lorlatinib in the first-line treatment of ALK-positive lung cancer

2025-10-19 11:44:20

Check Details
Has the ALK inhibitor lorlatinib been approved for marketing in China? How to buy?

2025-10-19 11:44:20

Check Details
Lorlatinib is expected to improve the treatment of ALK-positive lung cancer

2025-10-19 11:44:20

Check Details
Therapeutic efficacy data of the third-generation drug lorlatinib for lung cancer

2025-10-19 11:44:20

Check Details
Category
相关知识